Eurofarma Laboratórios S.A. agreed to acquire a portfolio of 12 products in Latin America from Hypera S.A. (BOVESPA:HYPE3) for approximately $160 million on March 17, 2020. Eurofarma Laboratórios S.A. entered into a Quota Purchase Agreement to acquire a portfolio of 12 products in Latin America from Hypera S.A. on March 18, 2020. Eurofarma will acquire the portfolio of 12 selected over the counter and prescription pharmaceutical products in Argentina, Colombia, Ecuador, Mexico, Panama and Peru. The drugs reported total sales of $38 million.

The transaction is subject to certain conditions precedent, including the closing between Hypera and Takeda of a portfolio of select non-core products in Latin America, and the approval of the transaction by the relevant antitrust authorities and regulatory authority. The Board of Directors of Hypera unanimously resolved to approve the execution of agreement on March 17, 2020. As on August 23, 2020, the transaction has been approved by Administrative Council for Economic Defense. Paulo Rage and Barbara Leite of Tauil & Chequer Advogados and Raúl Fernández-Briseño and Francisco Güémez of Mayer Brown Mexico, S.C acted as legal advisors for Eurofarma Laboratórios S.A. Marcos Rafael Flesch, Ana Carolina Castro Reis Passos, Isabel Neves de Trigueros, Fernando Pinto Xavier Filho and Rodolpho Clemente of Mayer Brown Mexico, S.C acted as legal advisors for Hypera S.A.

Eurofarma Laboratórios S.A. cancelled the acquisition of a portfolio of 12 products in Latin America from Hypera S.A. (BOVESPA:HYPE3) on March 17, 2021.